Advertisement

Supportive Care in Cancer

, Volume 25, Issue 4, pp 1183–1189 | Cite as

Validation of the Chinese version of functional assessment of anorexia-cachexia therapy (FAACT) scale for measuring quality of life in cancer patients with cachexia

  • Ting Zhou
  • Kaixiang Yang
  • Sudip Thapa
  • Qiang Fu
  • Yongsheng Jiang
  • Shiying YuEmail author
Original Article

Abstract

Purpose

The assessment of quality of life (QOL) is an important part of cachexia management for cancer patients. Functional assessment of anorexia-cachexia therapy (FAACT), a specific QOL instrument for cachexia patients, has not been validated in Chinese population. The aim of this study was to validate the FAACT scale in Chinese cancer patients for its future use.

Methods

Eligible cancer patients were included in our study. Patients’ demographic and clinical characteristics were collected from the electronic medical records. Patients were asked to complete the Chinese version of FAACT scale and the MD Anderson symptom inventory (MDASI), and then the reliability and validity were analyzed.

Results

A total of 285 patients were enrolled in our study, data of 241 patients were evaluated. Coefficients of Cronbach’s alpha, test-retest and split-half analyses were all greater than 0.8, which indicated an excellent reliability for FAACT scale. In item-subscale correlation analysis and factor analysis, good construct validity for FAACT scale was found. The correlation between FAACT and MDASI interference subscale showed reasonable criterion-related validity, and for further clinical validation, the FAACT scale showed excellent discriminative validity for distinguishing patients in different cachexia status and in different performance status.

Conclusions

The Chinese version of FAACT scale has good reliability and validity and is suitable for measuring QOL of cachexia patients in Chinese population.

Keywords

Cancer cachexia Functional assessment of anorexia-cachexia therapy Quality of life Questionnaire validity MD Anderson symptom inventory 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and publication of this article.

References

  1. 1.
    Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. The Lancet Oncology 12(5):489–495. doi: 10.1016/S1470-2045(10)70218-7 CrossRefPubMedGoogle Scholar
  2. 2.
    Penet MF, Bhujwalla ZM (2015) Cancer cachexia, recent advances, and future directions. Cancer J 21(2):117–122. doi: 10.1097/PPO.0000000000000100 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Scarpi E, Maltoni M, Miceli R, Mariani L, Caraceni A, Amadori D, Nanni O (2011) Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium. Oncologist 16(12):1793–1799. doi: 10.1634/theoncologist.2011-0130 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Go SI, Park MJ, Song HN, Kang MH, Park HJ, Jeon KN, Kim SH, Kim MJ, Kang JH, Lee GW (2016) Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 24(5):2075–2084. doi: 10.1007/s00520-015-2997-x CrossRefGoogle Scholar
  5. 5.
    Mercadante S, Valle A, Porzio G, Aielli F, Adile C, Casuccio A, Home Care-Italy G (2013) Prognostic factors of survival in patients with advanced cancer admitted to home care. J Pain Symptom Manag 45(1):56–62. doi: 10.1016/j.jpainsymman.2011.12.288 CrossRefGoogle Scholar
  6. 6.
    Couch ME, Dittus K, Toth MJ, Willis MS, Guttridge DC, George JR, Barnes CA, Gourin CG, Der-Torossian H (2015) Cancer cachexia update in head and neck cancer: definitions and diagnostic features. Head & Neck 37(4):594–604. doi: 10.1002/hed.23599 CrossRefGoogle Scholar
  7. 7.
    Mondello P, Mian M, Aloisi C, Fama F, Mondello S, Pitini V (2015) Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options. Nutr Cancer 67(1):12–26. doi: 10.1080/01635581.2015.976318 CrossRefPubMedGoogle Scholar
  8. 8.
    Kimura M, Naito T, Kenmotsu H, Taira T, Wakuda K, Oyakawa T, Hisamatsu Y, Tokito T, Imai H, Akamatsu H, Ono A, Kaira K, Murakami H, Endo M, Mori K, Takahashi T, Yamamoto N (2015) Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 23(6):1699–1708. doi: 10.1007/s00520-014-2534-3 CrossRefGoogle Scholar
  9. 9.
    Srdic D, Plestina S, Sverko-Peternac A, Nikolac N, Simundic AM, Samarzija M (2016) Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. doi: 10.1007/s00520-016-3287-y CrossRefGoogle Scholar
  10. 10.
    Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 15(8):2920–2926. doi: 10.1158/1078-0432.CCR-08-2242 CrossRefGoogle Scholar
  11. 11.
    Go SI, Park MJ, Song HN, Kim HG, Kang MH, Lee HR, Kim Y, Kim RB, Lee SI, Lee GW (2016) Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachex Sarcopenia Muscle. doi: 10.1002/jcsm.12115 CrossRefGoogle Scholar
  12. 12.
    Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. The Lancet Oncology 9(7):629–635. doi: 10.1016/S1470-2045(08)70153-0 CrossRefPubMedGoogle Scholar
  13. 13.
    Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study G (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83(6):1345–1350CrossRefGoogle Scholar
  14. 14.
    Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, Katakami N, Yokoyama T, Yoshimori K, Takiguchi Y, Hataji O, Takeda Y, Aoe K, Kim YH, Yokota S, Tabeta H, Tomii K, Ohashi Y, Eguchi K, Watanabe K (2016) Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. doi: 10.1007/s00520-016-3156-8 CrossRefGoogle Scholar
  15. 15.
    Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J, Aaronson NK (1998) The European Organization for Research and Treatment of cancer approach to developing questionnaire modules: an update and overview. EORTC quality of life study group. Quality of Life Research: an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation 7(4):291–300CrossRefGoogle Scholar
  16. 16.
    Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 11(3):570–579CrossRefGoogle Scholar
  17. 17.
    Cohen SR, Mount BM, Strobel MG, Bui F (1995) The McGill quality of life questionnaire: a measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med 9(3):207–219CrossRefGoogle Scholar
  18. 18.
    Cheung YB, Goh C, Thumboo J, Khoo KS, Wee J (2005) Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23(22):4936–4944. doi: 10.1200/JCO.2005.07.141 CrossRefGoogle Scholar
  19. 19.
    King MT, Bell ML, Costa D, Butow P, Oh B (2014) The quality of life questionnaire core 30 (QLQ-C30) and functional assessment of cancer-general (FACT-G) differ in responsiveness, relative efficiency, and therefore required sample size. J Clin Epidemiol 67(1):100–107. doi: 10.1016/j.jclinepi.2013.02.019 CrossRefPubMedGoogle Scholar
  20. 20.
    Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Von Roenn J, Leslie WT (2000) Re-validation and shortening of the functional assessment of anorexia/cachexia therapy (FAACT) questionnaire. Quality of Life Research: an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation 9(10):1137–1146CrossRefGoogle Scholar
  21. 21.
    Blauwhoff-Buskermolen S, Ruijgrok C, Ostelo RW, de Vet HC, Verheul HM, de van der Schueren MA, Langius JA (2016) The assessment of anorexia in patients with cancer: cut-off values for the FAACT-A/CS and the VAS for appetite. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 24(2):661–666. doi: 10.1007/s00520-015-2826-2 CrossRefGoogle Scholar
  22. 22.
    Salsman JM, Beaumont JL, Wortman K, Yan Y, Friend J, Cella D (2015) Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 23(5):1355–1364. doi: 10.1007/s00520-014-2484-9 CrossRefGoogle Scholar
  23. 23.
    Richards CH, Roxburgh CS, MacMillan MT, Isswiasi S, Robertson EG, Guthrie GK, Horgan PG, McMillan DC (2012) The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One 7(8):e41883. doi: 10.1371/journal.pone.0041883 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kim EY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM (2015) Prognostic significance of CT-determined sarcopenia in patients with small-cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10(12):1795–1799. doi: 10.1097/JTO.0000000000000690 CrossRefGoogle Scholar
  25. 25.
    Wang XS, Wang Y, Guo H, Mendoza TR, Hao XS, Cleeland CS (2004) Chinese version of the M. D. Anderson symptom inventory: validation and application of symptom measurement in cancer patients. Cancer 101(8):1890–1901. doi: 10.1002/cncr.20448 CrossRefPubMedGoogle Scholar
  26. 26.
    Kim H, Park HC, Yoon SM, Kim TH, Kim J, Kang MK, Jung J, Kim SW, Yea JW, Park SH, Park YS (2016) Evaluation of quality of life using a tablet PC-based survey in cancer patients treated with radiotherapy: a multi-institutional prospective randomized crossover comparison of paper and tablet PC-based questionnaires (KROG 12-01). Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. doi: 10.1007/s00520-016-3280-5 CrossRefGoogle Scholar
  27. 27.
    Schmidt H, Merkel D, Koehler M, Flechtner HH, Sigle J, Klinge B, Jordan K, Vordermark D, Landenberger M, Jahn P (2016) PRO-ONKO-selection of patient-reported outcome assessments for the clinical use in cancer patients-a mixed-method multicenter cross-sectional exploratory study. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 24(6):2503–2512. doi: 10.1007/s00520-015-3055-4 CrossRefGoogle Scholar
  28. 28.
    Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, Katakami N, Yokoyama T, Yoshimori K, Takiguchi Y, Hataji O, Takeda Y, Aoe K, Kim YH, Yokota S, Tabeta H, Tomii K, Ohashi Y, Eguchi K, Watanabe K (2016) Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 24(8):3473–3480. doi: 10.1007/s00520-016-3156-8 CrossRefGoogle Scholar
  29. 29.
    Wu XD, Qin HY, Zhang JE, Zheng MC, Xin MZ, Liu L, Wu XJ, Jiang CN, Zhang MF (2015) The prevalence and correlates of symptom distress and quality of life in Chinese oesophageal cancer patients undergoing chemotherapy after radical oesophagectomy. European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society 19(5):502–508. doi: 10.1016/j.ejon.2015.02.010 CrossRefGoogle Scholar
  30. 30.
    Cannabis In Cachexia Study G, Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T (2006) Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-Cachexia-Study-Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 24(21):3394–3400. doi: 10.1200/JCO.2005.05.1847 CrossRefGoogle Scholar
  31. 31.
    Maccio A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, Cau MC, Panzone F, Mantovani G (2012) A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 124(3):417–425. doi: 10.1016/j.ygyno.2011.12.435 CrossRefPubMedGoogle Scholar
  32. 32.
    Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. The Lancet Oncology 17(4):519–531. doi: 10.1016/S1470-2045(15)00558-6 CrossRefPubMedGoogle Scholar
  33. 33.
    Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J (2015) Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. The Lancet Oncology 16(1):108–116. doi: 10.1016/S1470-2045(14)71154-4 CrossRefPubMedGoogle Scholar
  34. 34.
    Zhou HJ, So JB, Yong WP, Luo N, Zhu F, Naidoo N, Li SC, Yeoh KG (2012) Validation of the functional assessment of cancer therapy-gastric module for the Chinese population. Health and Quality of Life Outcomes 10:145. doi: 10.1186/1477-7525-10-145 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    LeBlanc TW, Samsa GP, Wolf SP, Locke SC, Cella DF, Abernethy AP (2015) Validation and real-world assessment of the functional assessment of anorexia-cachexia therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS). Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 23(8):2341–2347. doi: 10.1007/s00520-015-2606-z CrossRefGoogle Scholar
  36. 36.
    Maeda H, Sato M, Kobayashi M, Takiguchi N, Yoshikawa T, Yoshino S, Yoshida K, Tsuburaya A, Sakamoto J, Morita S (2016) Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. doi: 10.1007/s00520-016-3290-3 CrossRefGoogle Scholar
  37. 37.
    Su Y, Mo CW, Cheng WQ, Wang L, Xu Q, Wu ZC, Wu ZL, Liu LZ, Chen XL (2016) Development and validation of quality of life scale of nasopharyngeal carcinoma patients: the QOL-NPC (version 2). Health and Quality of Life Outcomes 14(1):76. doi: 10.1186/s12955-016-0480-0 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Wan C, Zhang D, Yang Z, Tu X, Tang W, Feng C, Wang H, Tang X (2007) Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer. Breast Cancer Res Treat 106(3):413–418. doi: 10.1007/s10549-007-9511-1 CrossRefPubMedGoogle Scholar
  39. 39.
    Browne MW, Cudeck R (1993) Alternative ways of assessing model fit. In: Bollen KA, Long JS (eds) Testing structural equation models. Sage, Beverly Hills, CAGoogle Scholar
  40. 40.
    Hair JFAR, Tatham RL, Black WC (1998) Multivariate data analysis, 5th edn. Prentice Hall, Upper Saddle River, NJGoogle Scholar
  41. 41.
    Park JH, Bae SH, Jung YS, Jung YM (2015) The psychometric properties of the Korean version of the functional assessment of cancer therapy-cognitive (FACT-cog) in Korean patients with breast cancer. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 23(9):2695–2703. doi: 10.1007/s00520-015-2632-x CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Ting Zhou
    • 1
  • Kaixiang Yang
    • 2
  • Sudip Thapa
    • 1
  • Qiang Fu
    • 1
  • Yongsheng Jiang
    • 1
  • Shiying Yu
    • 1
    Email author
  1. 1.Cancer Center of Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanPeople’s Republic of China
  2. 2.Department of Orthopedic Surgery, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations